Blinatumomab
Brand Names: Blincyto
Methodology & AI Transparency ⓘ
Blinatumomab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage blincyto: is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- 2 Real-world patient consensus: Real-world cohort score of 80% across 21 de-identified Blinatumomab entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $67.22 mail/discount cash up to $164.69 uninsured retail (federal NADAC $1.4500).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Blinatumomab include nausea (10.5%), headache (9.1%), diarrhea (7.8%).
Ask our AI Specialists anything about Blinatumomab
Blinatumomab Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage blincyto: is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
12.1 Mechanism of Action Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, which result in redirected lysis of CD19+ cells.
Pharmacokinetic profiling of Blinatumomab demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–18 hour t½ intervals for Blinatumomab with Approximately 72% to 84% enteral uptake across labeled Blinatumomab strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar blinatumomab conjugates, reaching clinical onset within maximum serum exposure occurs 2–5 hours after blinatumomab dosing.
Titration schedules for Blinatumomab (Kit → Therapeutic monitoring titration for Blinatumomab (fda prescription therapeutic agent)) require excluding 4 contraindications blincyto is contraindicated in patients with known hypersensitivity to blinatumomab or to any component of the product formulation.; known hypersensitivity to blinatumomab or to any component of the product formulation.; real-world patient logs highlight nausea (10.5% of reports), headache (9.1% of reports), diarrhea (7.8% of reports) alongside a 80.00% Worth-It consensus.
Prothrombin time and INR stability may fluctuate when Blinatumomab is added to chronic warfarin regimens.
Verify medication reconciliation lists so Blinatumomab is not inadvertently duplicated with another fda prescription therapeutic agent.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS BLINCYTO is contraindicated in patients with known hypersensitivity to blinatumomab or to any component of the product formulation.
- Known hypersensitivity to blinatumomab or to any component of the product formulation.
Logged Side-Effect Incidence (21 Reports)
Blinatumomab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Blinatumomab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute Blinatumomab was associated with greater benefit in terms of OS and EFS relative to SC. Leukemia research • 2024-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39214018 ↗ |
| Can This Approach Help? Inside the Latest Research on Biomarkers associated with blinatumomab outcomes in acute lymphoblastic No examined biomarkers were significant for the risk of grade ≥3 side effects. Leukemia • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33542479 ↗ |
Blinatumomab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.4500/unit (~$43.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $164.69 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $67.22 / mo | View logs ↓ |
Blinatumomab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Blinatumomab RxNorm Concept ID | 1597262 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $164.69 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $67.22 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Blinatumomab Patient Community, Cohort Filters & Dosage Logs
Deterministic Blinatumomab reference combining NIH RxNorm (1597262), Medicaid NADAC ($1.4500/unit), and anonymous cohort outcomes (80% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Blinatumomab community threads and patient logs by age, biological sex, dosage, and treatment duration.